ENZON PHARM (EZ1.SG)
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon… Read more
ENZON PHARM (EZ1.SG) (EZ1) - Net Assets
Latest net assets as of September 2025: €-923.00K EUR
Based on the latest financial reports, ENZON PHARM (EZ1.SG) (EZ1) has net assets worth €-923.00K EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€43.69 Million) and total liabilities (€44.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-923.00K |
| % of Total Assets | -2.11% |
| Annual Growth Rate | -14.29% |
| 5-Year Change | -59.13% |
| 10-Year Change | N/A |
| Growth Volatility | 35.42 |
ENZON PHARM (EZ1.SG) - Net Assets Trend (2016–2024)
This chart illustrates how ENZON PHARM (EZ1.SG)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ENZON PHARM (EZ1.SG) (2016–2024)
The table below shows the annual net assets of ENZON PHARM (EZ1.SG) from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.01 Million | -14.18% |
| 2023-12-31 | €3.50 Million | +2.88% |
| 2022-12-31 | €3.41 Million | -30.01% |
| 2021-12-31 | €4.87 Million | -33.86% |
| 2020-12-31 | €7.36 Million | +21.55% |
| 2019-12-31 | €6.05 Million | -59.61% |
| 2018-12-31 | €14.99 Million | +63.97% |
| 2017-12-31 | €9.14 Million | -11.49% |
| 2016-12-31 | €10.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ENZON PHARM (EZ1.SG)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1050000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €72.90 Million | 2423.54% |
| Total Equity | €3.01 Million | 100.00% |
ENZON PHARM (EZ1.SG) Competitors by Market Cap
The table below lists competitors of ENZON PHARM (EZ1.SG) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LIQUID META CAPITAL HLDGS
F:N5F
|
$1.47 Million |
|
Patriot Gold Corp
PINK:PGOL
|
$1.47 Million |
|
Centogene N.V.
NASDAQ:CNTGF
|
$1.47 Million |
|
IPSEN (I7G.SG)
STU:I7G
|
$1.47 Million |
|
HANOVER INSURANCE
BE:AF4
|
$1.47 Million |
|
iWallet Corporation
PINK:IWAL
|
$1.47 Million |
|
Bls Invest Danske Aktier Kl
CO:BLKDA
|
$1.47 Million |
|
8COMMON Ltd
AU:8CO
|
$1.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ENZON PHARM (EZ1.SG)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,505,000 to 3,008,000, a change of -497,000 (-14.2%).
- Net income of 778,000 contributed positively to equity growth.
- Dividend payments of 1,275,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €778.00K | +25.86% |
| Dividends Paid | €1.27 Million | -42.39% |
| Total Change | €- | -14.18% |
Book Value vs Market Value Analysis
This analysis compares ENZON PHARM (EZ1.SG)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.23x to 1.17x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.21 | €0.05 | x |
| 2018-12-31 | €0.34 | €0.05 | x |
| 2019-12-31 | €0.14 | €0.05 | x |
| 2020-12-31 | €0.10 | €0.05 | x |
| 2021-12-31 | €0.07 | €0.05 | x |
| 2022-12-31 | €0.05 | €0.05 | x |
| 2023-12-31 | €0.05 | €0.05 | x |
| 2024-12-31 | €0.04 | €0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ENZON PHARM (EZ1.SG) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 25.86%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2992.31%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 15.68x
- Recent ROE (25.86%) is above the historical average (11.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -10.90% | -13.44% | 0.74x | 1.09x | €-2.16 Million |
| 2017 | 59.55% | 64.98% | 0.88x | 1.04x | €4.53 Million |
| 2018 | 39.01% | 84.55% | 0.45x | 1.03x | €4.35 Million |
| 2019 | -16.17% | -472.95% | 0.03x | 1.07x | €-1.58 Million |
| 2020 | -17.81% | -2521.15% | 0.00x | 6.55x | €-2.05 Million |
| 2021 | -9.63% | -66.90% | 0.01x | 9.81x | €-955.80K |
| 2022 | -5.46% | -715.38% | 0.00x | 13.97x | €-526.70K |
| 2023 | 39.17% | 0.00% | 0.00x | 13.61x | €1.02 Million |
| 2024 | 25.86% | 2992.31% | 0.00x | 15.68x | €477.20K |
Industry Comparison
This section compares ENZON PHARM (EZ1.SG)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ENZON PHARM (EZ1.SG) (EZ1) | €-923.00K | -10.90% | N/A | $1.47 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |